<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942380</url>
  </required_header>
  <id_info>
    <org_study_id>1301261</org_study_id>
    <nct_id>NCT03942380</nct_id>
  </id_info>
  <brief_title>Cell-free Tumor DNA in Head and Neck Cancer Patients</brief_title>
  <official_title>Cell-free Tumor DNAand HPV-DNA in Blood Samples From Newly Diagnosed Patients With Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian von Buchwald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Otorhinolaryngology, Head and Neck Surgery and Audiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates if head and neck squamous cell carcinoma can be tracked with
      cell-free tumor DNA, RNA or HPV-DNA, in blood samples from patients referred with suspicion
      of cancer, and if it can be used in detecting recurrence in patients already diagnosed and
      treated for head and neck squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of head and neck cancer detected with a blood sample</measure>
    <time_frame>0 months</time_frame>
    <description>The primary outcome is to measure the percentage of head and neck squamous cell carcinomas that can be detected using a liquid biopsy (blood sample)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of head and neck cancer recurrence detected with a blood sample</measure>
    <time_frame>36 months</time_frame>
    <description>The primary outcome is to measure the percentage of recurrence in head and neck cancer patients through serial monitoring with liquid biopsies (blood sample)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cell-free tumor DNA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The aim is to differentiate between patients with head and neck cancer from those without based on a blood sample.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Identifying recurrence</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The aim is to identify recurrence through serial monitoring patients with blood samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liquid biopsy</intervention_name>
    <description>The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA</description>
    <arm_group_label>Cell-free tumor DNA</arm_group_label>
    <arm_group_label>Identifying recurrence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years old or older

          -  Suspicion of head and neck cancer

        Exclusion Criteria:

          -  Diagnosed with cancer within the last 3 years ( apart from basal cell carcinoma)

          -  Diagnosed with an inflammatory or haematological disease after the age of 18

          -  Received chemotherapy or immunosuppressive treatment within the last 3 years

          -  Underwent a FNA ( fine-needle aspiration biopsy) or a biopsy from the head and neck
             region within 1 week.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Von Buchwald, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Otorhinolaryngology, Head and Neck Surgery and Audiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Grønhøj, MD, Ph.D</last_name>
    <phone>004526276374</phone>
    <email>Christian.groenhoej@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Copenhagen, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Region Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Christian von Buchwald</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

